Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients

Glenmark Pharmaceuticals on Thursday said it has become the first
company in India to receive approval from Drug Controller General of
India (DCGI) to conduct clinical trials of Favipiravir antiviral
tablets for the treatment of COVID-19 patients.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-pharma-gets-dcgi-nod-for-clinical-trials-of-favipiravir-tablets-on-covid-19-patients/articleshow/75465661.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment